Neogenomics, Inc.
NEO
$8.75
$0.091.04%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 745.97M | 727.33M | 709.16M | 689.19M | 672.36M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 745.97M | 727.33M | 709.16M | 689.19M | 672.36M |
| Cost of Revenue | 424.46M | 413.44M | 401.36M | 386.95M | 374.48M |
| Gross Profit | 321.51M | 313.89M | 307.81M | 302.24M | 297.88M |
| SG&A Expenses | 353.72M | 352.86M | 350.80M | 345.13M | 336.81M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 814.61M | 803.38M | 788.02M | 766.93M | 745.01M |
| Operating Income | -68.64M | -76.05M | -78.86M | -77.74M | -72.65M |
| Income Before Tax | -102.19M | -110.27M | -113.99M | -105.45M | -78.65M |
| Income Tax Expenses | -2.98M | -2.24M | -522.00K | -1.41M | -1.06M |
| Earnings from Continuing Operations | -99.21 | -108.03 | -113.47 | -104.04 | -77.59 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -99.21M | -108.03M | -113.47M | -104.04M | -77.59M |
| EBIT | -68.64M | -76.05M | -78.86M | -77.74M | -72.65M |
| EBITDA | -2.13M | -8.22M | -9.24M | -6.58M | -641.00K |
| EPS Basic | -0.77 | -0.84 | -0.89 | -0.82 | -0.61 |
| Normalized Basic EPS | -0.31 | -0.34 | -0.35 | -0.33 | -0.30 |
| EPS Diluted | -0.77 | -0.84 | -0.89 | -0.82 | -0.61 |
| Normalized Diluted EPS | -0.31 | -0.34 | -0.35 | -0.33 | -0.30 |
| Average Basic Shares Outstanding | 514.18M | 512.39M | 510.90M | 509.44M | 507.89M |
| Average Diluted Shares Outstanding | 514.18M | 512.39M | 510.90M | 509.44M | 507.89M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |